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Of the adeno-associated viruses (AAVs), AAV9 is known for its capability to cross the
blood–brain barrier (BBB) and can, therefore, be used as a noninvasive method to target
the central nervous system. Furthermore, the addition of the peptide PhP.B to AAV9
increases its transduction across the BBB by 40-fold. Another neurotropic serotype,
AAV5, has been shown as a gene therapeutic delivery vehicle to ameliorate several
neurodegenerative diseases in preclinical models, but its administration requires invasive
surgery. In this study, AAV9-PhP.B and AAV5-PhP.B were designed and produced
in an insect cell–based system. To AAV9, the PhP.B peptide TLAVPFK was added,
whereas in AAV5-PhP.B (AQTLAVPFKAQAQ), with AQ-AQAQ sequences used to swap
with the corresponding sequence of AAV5. The addition of PhP.B to AAV5 did not
affect its capacity to cross the mouse BBB, while increased transduction of liver
tissue was observed. Then, intravenous (IV) and intrastriatal (IStr) delivery of AAV9-
PhP.B and AAV5 were compared. For AAV9-PhP.B, similar transduction and expression
levels were achieved in the striatum and cortex, irrespective of the delivery method
used. IStr administration of AAV5 resulted in significantly higher amounts of vector
DNA and therapeutic miRNA in the target regions such as striatum and cortex when
compared with an IV administration of AAV9-PhP.B. These results illustrate the challenge
in developing a vector that can be delivered noninvasively while achieving a transduction
level similar to that of direct administration of AAV5. Thus, for therapeutic miRNA
delivery with high local expression requirements, intraparenchymal delivery of AAV5 is
preferred, whereas a humanized AAV9-PhP.B may be useful when widespread brain
(and peripheral) transduction is needed.
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GRAPHICAL ABSTRACT | Comparison of AAV5 vs. AAV9-PhP.B delivered intravenous or intrastriatal. Irrespective of the two delivery methods, similar transduction
in the cortex and striatum is achieved with AAV9-PhP.B. In contrast, AAV5—when injected directly into the striatum—obtains high transduction levels in the
cortex and striatum.
INTRODUCTION
Neurodegenerative diseases are a heterogeneous group of
multisystem disorders affecting the central nervous system
(CNS), and treatment options for those are limited. An
important and challenging aspect of the treatment of these
diseases is efficient drug target delivery. Viral vectors harboring
therapeutic nucleic acid molecules have to be delivered to
the CNS to accomplish their therapeutic action at the desired
site. The delivery of viral vectors is a part of molecular
neurosurgery, thereby treating disease on a molecular level.
Various disease-modifying therapies are in the (pre)clinical stage
for neurodegenerative diseases based on adeno-associated virus
(AAV) as the delivery tool of nucleic acids (Chen et al., 2020;
Mijanović et al., 2020).
One of the examples of such a preclinical program is for
the treatment of Huntington’s disease (HD). Intrastriatal (IStr)
delivery of AAV carrying a huntingtin silencing miRNA resulted
in a successful reduction in huntingtin mRNA and protein in
the brains of mouse and minipig HD models (Evers et al.,
2018; Spronck et al., 2019). The produced miRNA lowered
cytoplasmic and nuclear gene expression and showed therapeutic
spread through extracellular vesicles without off-target effects
(Keskin et al., 2019). This miRNA technology has also been
used as silencing strategies for Spinocerebellar Ataxia Type 3
(Martier et al., 2019b) and Amyotrophic Lateral Sclerosis (ALS)
(Martier et al., 2019a).
The direct IStr administration of AAV has been used to
supply the brain locally with the therapeutic doses of the miRNA
(Evers et al., 2018; Spronck et al., 2019). However, this invasive
intervention requires a well-equipped and trained neurosurgical
team. Intravenous (IV) administration would be an attractive
alternative since it is less invasive. Nevertheless, an AAV capsid
that can cross the blood–brain barrier (BBB) is required when
targeting the CNS by IV administration. AAV9 has been shown to
have this capability, especially in neonates (Foust et al., 2008). The
number of vector copies needed to reach therapeutic doses in the
brain may lead to elevated aminotransferase levels, an indicator
of liver damage (Mendell et al., 2017). For the probable cause
of systemic adverse events, it is currently challenging to use IV
administration of AAV9 for neurodegenerative diseases in adults.
Various attempts have been undertaken to improve the
capability and efficiency of AAV to cross the BBB. A variant
of AAV9, named AAV9-PhP.B, was reported to enhance brain
tissue transduction, such as the cortex, by 40-fold compared with
its AAV9 ancestor (Deverman et al., 2016). The enhancement
of AAV9 by PhP.B appears to occur only in rodents (Hordeaux
et al., 2018), with a preference for the C57Bl/6 strain, the
strain in which PhP.B was developed and tested (Hordeaux
et al., 2018). Studies in nonhuman primates (Liguore et al.,
2019) and marmosets (Matsuzaki et al., 2018) have not shown
any increase in the transduction levels of AAV9-PhP.B when
compared to AAV9. PhP.B binds to the Ly6a receptor, a
GPI (glycophosphatidylinositol)-anchored surface protein highly
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expressed in the microvascular endothelial cells of C57Bl/6 mice
(Hordeaux et al., 2019; Huang et al., 2019). Unfortunately, Ly6a
is absent in endothelial cells of primates (Hordeaux et al., 2019),
which explains why no increase is observed in BBB crossing
compared with AAV9. These results limit the use of PhP.B-
containing vectors in humans. However, AAV9-PhP.B can still be
used as a benchmark for preclinical studies in C57Bl/6 mice. The
knowledge gained from these studies could be used to rationally
develop novel vectors that cross the BBB.
PhP.B is constructed by inserting a 7-mer peptide at position
I-588. The insertion site is located outside of the capsid on the tip
of a loop at the 3-fold axis of symmetry, facilitating interaction
with the receptors of targeted cells. AAV9-PhP.B has shown to
be functional in mouse models. For example, AAV9-PhP.B-based
gene therapy has been shown to reduce α-synuclein pathology in
a preclinical mouse model (Morabito et al., 2017).
We hypothesized that the addition of PhP.B could also be
used to enhance BBB crossing of other serotypes. Zhang et al.
(2011) showed that the natural serotypes of AAV2 and AAV5
do not cross the BBB even in neonatal mice (Zhang et al.,
2011). AAV5 is the most divergent of the naturally occurring
AAVs. After local administration, AAV5 shows widespread
transduction of the brain (Samaranch et al., 2017), making
this vector a useful candidate to test the limits of PhP.B.
This widespread targeting has been shown in a variety of
animal models such as mice, rats, nonhuman primates, and
minipigs (Emborg et al., 2014; Miniarikova et al., 2017; Evers
et al., 2018; Caron et al., 2019). Furthermore, AAV5 has
been shown to specifically target astrocytes and specialized
neurons such as dopaminergic and motor neurons derived from
the human-induced pluripotential stem cells (Martier et al.,
2019a). In in addition to neuronal tropism AAV5 could be
delivered systemically in a noninvasive manner would be ideal.
Therefore, PhP.B was added to AAV5 to explore the enhanced
crossing of the BBB.
First, AAV5 and AAV9 were modified by inserting the 7-
mer PhP.B, and the vectors were produced in the baculovirus
expression system. This system facilitates scaling up production
(Kotin and Snyder, 2017). Then, these new capsids were evaluated
in vitro with respect to the green fluorescent protein (GFP)
expression and dose–response quantified by luciferase activity.
The capability of capsids to cross the BBB of mice was assessed
at a relatively low dose to remain below the saturation threshold.
Finally, IStr and IV delivery of AAV5 and AAV9-PhP.B were
compared for transduction and transgene expression in the
cortex and striatum.
MATERIALS AND METHODS
Vector Design and Production
The AAV9-PhP.B transfer plasmid was designed by adding the
PhP.B peptide to VP1 between amino acids 588 and 589 of
AAV9 adapted for baculovirus production. AAV5-PhP.B was
constructed by swapping in the 13-mer loop containing PhP.B,
as described in the study of Deverman et al. (2016), and
publicly available as sequence KU056473, shown in Figure 1A.
Baculovirus was produced by homologous recombination with
the transfer plasmids, as described earlier (Urabe et al., 2002;
Bosma et al., 2018). Expression cassettes containing either GFP,
Luc, or miRNA were generated correspondingly. To generate
AAV, Spodoptera frugiperda (SF) SF+ cells were triple-infected
with baculovirus containing capsid, expression cassette, and the
replicon enzyme. At 72 h postinfection, cells were lysed, and
the clarified lysate was purified on the ÄKTA explorer (FPLC
chromatography system, GE healthcare, United Kingdom) using
AVB sepharose (GE healthcare, United Kingdom). The vectors
were titrated by SYBR Green for quantitative PCR (qPCR)
using a primer pair binding to the promoter region CAG
(forward primer: GAG CCG CAG CCA TTG C and reverse
primer: CAC AGA TTT GGG ACA AAG GAA GT) or CMV
(forward primer: AATGGGCGGTAGGCGTGTA and reverse
primer: AGGCGATCTGACGGTTCACTAA) and expressed as
genome copies per ml (GC/ml).
In vitro Analysis
Of note, 1 × 105 CHO Lec-2 cells were seeded in a 24-well plate
and inoculated and incubated overnight. On the following day,
cells were inoculated with 1 × 1011 GC/well for a multiplicity
of infection (MOI) of 1 × 106 in triplicate for each capsid.
GFP expression was visualized 3–7 days postinoculation. CHO
Lec-2 cells were seeded at a density of 2.5 × 104 cells/well in
duplicate in a black 96-well plate and inoculated in a 10-fold serial
dilution starting at MOI of 4 × 106 of each capsid containing a
luciferase expression cassette. Plates were incubated at 37◦C for
approximately 20 h and subsequently analyzed. 1 × 105 HuH-
7 cells or 5 × 104 CHO Lec-2 cells were seeded in triplicate
in two 24-well plate and inoculated with an MOI of 1 × 105
incubated for 20 h. One plate was used for luciferase analysis and
the other for DNA.
Luciferase assay was carried out using the One-Glo Luciferase
Assay System (E6120, Promega, Madison, United States)
according to the instruction of the manufacturer. DNA was
extracted from cell lysate using the AllPrep kit (QIAGEN,
Germany) according to the instruction of the manufacturer.
Vector DNA was detected by qPCR using SYBR Green primers
binding to the CMV promoter (forward primer: AAT GGG CGG
TAG GCG TGTA and reverse primer: CAC AGA TTT GGG
ACA AAG GAA GT).
Animal Studies
All animal studies described were approved by the local
ethics committee for animal experimentation. Female, young
adult C57Bl/6 mice (Janvier Labs, France) were used for
all experiments. For IV administration, 8 µl/g body weight
of each viral vector preparation was injected into the tail
vein. For IStr administration, animals were anesthetized with
Hypnorm/Dormicum, and an incision was made in the skin
of the head. A small hole was drilled in the skull, and the
striatum was stereotactically approached. A 2 µl of vehicle or
AAV-miRNA was injected into the striatum in both hemispheres
(Anteroposterior = +0.8 mm; mediolateral = ±1.8 mm;
Dorsal/Ventral = −3.0 mm) using a 30-Ga needle (BD, Becton,
Dickinson and Company, NJ, United States) and attached by
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FIGURE 1 | Overview of AAV-PhP.B capsids and in vitro testing. (A) Alignment of AAV5, AAV5-PhP.B, AAV9, and AAV9-PhP.B at PhP.B insertion. (B) Binding by
AAV9 of CHO Lec-2 cells due to the modification of the cell surface in glycan receptor exposing galactose, whereas AAV-5 transduces Huh-7 cells through binding
to sialic acid. Receptors on the cell surface are depicted in this figure. (C) Schematic overview of the expression cassette containing the cytomegalovirus (CMV) early
enhancer element and chicken beta-actin promoter (CAG), green fluorescent protein (GFP), and poly(A) tail. CHO Lec-2 cells were inoculated in triplicate with GFP
encoding constructs of each capsid. All capsids are capable of inducing GFP expression at 7 days postinoculation. (D) Graphical representation of expression
cassette used containing CMV-promoter-luciferase gene and poly(A) tail. A dose–response of each capsid in CHO Lec-2 cells measured as relative luminescence
(RLU). A total of 2 × 104 cells/well were infected in a serial dilution starting at a multiplicity of infection (MOI) of 4 × 106 cells/well in a 96-well plate. (E) Inoculation of
HuH-7 cells with AAV vectors. The addition of PhP.B to AAV-5 resulted in a decreased transduction in both cell types. Experiments were performed in triplicate in a
24-well plate, seeding 1 × 105 cells/well for HuH-7 cells. AAV5, orange bar; AAV5-PhP.B, pink bar; AAV9, light green; and AAV9-PhP.B, dark green. Asterisks
indicate a statistical significance of p ≤ 0.005.
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TABLE 1 | Overview of injection routes, vectors, and dosage used.
Study Vectors Injection route Volume (µl) Total dose (GC/mouse) Titer (GC/ml)






IV 200/25 gr 2,5 × 1011 1 × 1012
AAV9-PhP.B transduction of CNS AAV9-PhP.B-GFP IV 200/25 gr 4 × 1012 1,6 × 1013
AAV5 vs. AAV9-PhP.B AAV5-miRNA
AAV9-miRNA
IV 160/20 gr* 4 × 1012 2,7 × 1013
IStr 4 (2/hemisphere) 1 × 1011 2,7 × 1013
*Mice were 6 weeks old at the start of the experiment.
tubing to a 10-µl Hamilton syringe at a rate of 0.5 µl/min. After
surgery, mice were administered buprenorphine (Temgesic) as
pain relief. An overview of injection routes, vectors, and dosage
used is given in Table 1.
Vector Distribution and GFP Expression
At 4 or 6 weeks postinjection, animals were humanely euthanized,
and organs were dissected and frozen at −80◦C. For the first
experiment, in comparison with capsids at a low dose, the
left hemisphere was used for molecular analysis and the other
half fixed in 4% paraformaldehyde for histology. For the last
experiment, both left and right hemispheres were frozen for the
vector distribution analysis.
Organ pieces were pulverized to a powder using the
cryoPREP system (Covaris, Woburn, MA, United States).
Approximately ± 10-mg powder was used to extract DNA using
the DNeasy R© 96 Blood and Tissue kit (QIAGEN, Germany).
The presence of vector DNA was detected and quantified
by qPCR using TaqMan primers and probe binding to CAG
promoter (forward primer: GAG CCG CAG CCA TTG C,
reverse primer: CAC AGA TTT GGG ACA AAG GAA GT,
and probe: ATG GTA ATC GTG CGA GAG GGC GC).
Vector DNA genome copies per µg DNA were quantified by
interpolating from a standard line prepared from the plasmid
of the expression cassette. RNA was isolated from powder
using the RNeasy R© Plus Mini Kit (74136) from QIAGEN,
Germany. Total RNA was reverse-transcribed to cDNA using
the Maxima First-Strand kit (R1362, Thermo Fisher, Waltham,
MA, United States), RNA expression was quantified by using
primers binding to GFP (forward primer: AGC AAA GAC CCC
AAC GAG AA, reverse primer: GCG GCG GTC ACG AAC
TC, and probe: CGC GAT CAC ATG GTC CTG CT) and
GAPDH (TaqMan expression array from Thermo Fisher, Paisley,
United Kingdom) as a housekeeping gene for reference. RNA
expression was calculated using the 1CT method normalized to
the housekeeping gene.
microRNA TaqMan Assay
For the detection of the expressed microRNA, pulverized
cortical and striatal tissue was subjected to the Direct-zol kit
(R2061, ZYMO Research, Irvine United States) according to the
protocol of the manufacturer. RNA was reverse-transcribed into
cDNA using the TaqMan R© MicroRNA Reverse Transcription Kit
(Applied Biosystems, 4366597, Waltham, MA, United States).
Diluted samples of each cDNA sample were subjected to TaqMan
qPCR using a primer–probe set specific for miRNA and an
internal control miRNA (U6).
Graphs, Statistical Analysis, and Figures
The statistical analysis and graphs were generated using
GraphPad, www.graphpad.com [GraphPad Prism version 8.4.2.
(679) for Windows, GraphPad Software, San Diego, CA, United
States]. To compare groups, a one-way ANOVA was used,
followed by the Tukey’s multiple comparisons test. Figures with
cartoons were created using biorender.com. Graphical Abstract
was made by Sabela DeScience.
Histology
Of note, 24–48 h after immersion fixation in 4%
paraformaldehyde, brains were embedded in 10% gelatin
(Difco) in a phosphate-buffered saline (PBS). Embedded tissue
was sectioned on a Vibratome. Coronal sections were collected
in PBS in series at a thickness of 50 µM. Immunohistochemistry
(IHC) was performed on the free-floating sections. Endogenous
peroxidase block was performed by incubating sections for 1 h
in 1% H2O2/30% ethanol in PBS. Sections were washed three
times with washing buffer (PBS/0.05% Tween). Nonspecific
blocking was performed by incubating sections for 1 h in
PBS supplemented with 4% bovine serum albumin (BSA)
and 5% normal goat serum (NGS). Subsequently, sections
were incubated overnight with primary antibody against GFP
(Abcam ab290, Cambridge, United Kingdom), diluted 1:1000
in PBS/1% BSA/1.25% NGS/0.5% Tween, and incubated for
1 h with horseradish peroxidase (HRP)-conjugated anti-rabbit
before detection with 3,3′-diaminobenzidine (DAB) according
to instructions of the manufacturer (Dako EnVision kit K4009,
Agilent, Santa Clara, CA, United States). Subsequently, they were
dehydrated through ethanol series, xylene, and embedded in
Entellan before microscopic analysis.
RESULTS
Design and in vitro Testing of AAV-PhP.B
Capsids
To ensure that the vectors could be adapted to our production
system, PhP.B was added to AAVs adapted for the baculovirus
expression system. For AAV9, PhP.B was added at the same
position, I-588, as described in the study of Deverman et al.
(2016).
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Earlier attempts to modify AAV5 at the corresponding
position I575 were not successful (Khabou et al., 2016). An
alignment of AAV5 and AAV9-PhP.B shows sequence similarity
outside of the known variable regions, forming a loop at
the 3-fold axis of symmetry (Figure 1A). This loop facilitates
interaction with the receptors of targeted cells. To add this loop
to AAV5, AAV5-PhP.B (i.e., AQTLAVPFKAQAQ) was made by
swapping in the flaking regions of AAV9-PhP.B containing the
peptide (Figure 1A).
The new capsids were tested for transduction efficacy in vitro
using Chinese hamster ovary (CHO) Lec-2 cells and HuH-
7 cells. Having an easily accessible nonmurine cell line is
essential to set up future potency experiments. CHO Lec-
2 cells are deficient in monophosphate-SA (CMP-SA) Golgi
transporter. Therefore, N- and O-glycans of these cells only
contain galactose residues, as depicted in Figure 1B. CHO Lec-
2 cells are suitable for studying AAV9 transduction in vitro as
this virus uses galactose residues to enter the cell (Bell et al.,
2012). HuH-7 cells were used to study AAV5 preferential in vitro
transduction by sialic acid residues. HuH-7 cells are human
differentiated hepatocytes derived from a cellular carcinoma cell
line (Figure 1B).
The CHO Lec-2 cells were inoculated with each capsid
at an MOI of 1 × 106 GC/cell using GFP as a transgene
and monitored over time to assess the ability of capsids to
express a transgene. All capsids showed GFP expression 7 days
after inoculation (Figure 1C). To verify the potency of AAV-
PhP.B, CHO Lec-2 cells were transduced with each capsid in
a 10-fold serial dilution, starting with an MOI of 4 × 106
GC/cell. A dose–response was observed for each capsid, showing
the potency of the capsids (Figure 1D). No difference was
found in the transduction efficiency of AAV9-PhP.B vs. AA9
(Figure 1D). As expected, the potency of AAV5 and AAV5-
PhP.B was lower. Surprisingly, in HuH7 cells, the addition of
PhP.B to AAV5 resulted in a significant reduction in transgene
activity (Figure 1E).
At a Low Dose, AAV9-PhP.B Can Cross
the BBB to Reach the Mouse Brain
AAV5, AAV5-PhP.B, AAV9, and AAV9-PhP.B were evaluated
in vivo in C57Bl/6 mice for their capacity to cross the BBB
following IV injection and a life period of 6 weeks. Mice were
administered a relatively low dose (2.5 × 1011 GC/mouse) of
each capsid containing GFP as transgene (Figure 2A). Vector
distribution was assessed in the cortex, striatum, and thalamus by
qPCR. Only AAV9-PhP.B showed significant transduction to all
three investigated brain areas (Figure 2B). However, the numbers
of vector copies were very low to generate a positive GFP staining
on IHC sections. The addition of the PhP.B peptide to AAV5 did
not alter the ability of this capsid to cross the BBB (Figure 2B).
AAV5-PhP.B Shows Increased GFP
mRNA Expression in Mice Liver
In vitro experiments showed a reduction in transduction and
luciferase expression in AAV5-PhP.B-transduced HuH-7 cells
compared with AAV5 and no difference between AAV9 and
AAV9-PhP.B. We also assessed the transduction of peripheral
organs in vivo and liver GFP mRNA expression in mice.
A trend is observed in the higher levels of AAV9 and AAV9-
PhP.B vector in the spleen. In the kidney, most of the vector
is found in animals administered with AAV9-PhP.B. For the
liver, there appears to be an equal distribution with the least
amount of vector DNA retrieved from mice administered with
AAV9-PhP.B-GFP (Figure 3A). GFP mRNA expression was
significantly higher in animals administered with AAV5-PhP.B
and AAV9 when compared to mice administered with AAV5 or
AAV9-PhP.B (Figure 3B).
FIGURE 2 | Vector distribution in brain regions of AAV-PhP.B-GFP-administered mice. (A) Mice (n = 5) were administered 2.5 × 1011 GC/mouse by intravenous (IV)
injection. The expression cassette used contained the CAG, GFP, and poly(A) tail. (B) Tissue was collected 6 weeks after surgery and analyzed for the distribution of
the vectors. Significantly more vector DNA was retrieved from the cortex, striatum, and thalamus of AAV-PhP.B-GFP-administered mice when compared to vehicle
(PBS). The statistical analysis was performed by a one-way ANOVA followed by the Tukey’s multiple comparisons test, comparing groups with vehicle. Asterisks
indicate a statistical significance of p ≤ 0.05.
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FIGURE 3 | Vector distribution in mice periphery after IV administration of AAV and liver expression. (A) Vector distribution in the spleen, kidney, and liver. (B) GFP
mRNA expression in the liver with elevated levels in AAV5-PhP.B compared with AAV5. Asterisks indicate a statistical significance of p ≤ 0.005.
Central Nervous System Transduction of
AAV9-PhP.B
Genomic copies of AAV were detected and quantified after IV
administration of AAV9-PhP.B. However, no GFP expression
was observed in brain sections (data not shown) using
the relatively low viral dose. To assess the extent of the
AAV9-PhP.B-mediated transduction, GFP-transgene-carrying
AAV9-PhP.B was administered at a relatively high dose (4× 1012
GC/mouse) to demonstrate the presence of transgene protein
within the range of detection (Figure 4A). GFP expression was
observed throughout the brain from the medulla to the frontal
cortex. Positive neurons and astrocytes were identified by shape
and location in the medulla (Figure 4B), the locus coeruleus
(Figure 4C), the thalamus (Figure 4D), the hippocampus
(Figure 4E), the striatum (Figure 4F), and the cortex (Figure 4G).
These results highlight the potential of AAV9-PhP.B to express
transgene throughout the CNS.
Intrastriatal Delivery of AAV5-miRNA
Results in High Distribution and Levels of
microRNA in Mouse Brain
After establishing that AAV9-PhP.B delivers transgene
throughout the mouse brain, we assessed if AAV9-PhP.B
could be used for predominantly adult-onset diseases such as
HD or Parkinson’s disease. For HD, various huntingtin-gene-
expression-lowering strategies are in development (Miniarikova
et al., 2018). At the moment, in preclinical studies, IStr
administration is the method applied to reach the areas affected
in HD. This experiment also aimed to evaluate if AAV9-PhP.B
administered by IV could be used as a noninvasive alternative to
deliver miRNA in mice.
AAV5 or AAV9-PhP.B containing a miRNA expression
cassette (Figure 5A) was produced and administered IStr
(1 × 1011 GC/mouse) or IV (4 × 1012 GC/mouse) at an equal
concentration (2.7 × 1013 GC/ml), adjusting the volume to
the method used (Figure 5B). This is the highest dose that
could be produced without the possible formation of aggregates.
No significant difference was observed when AAV9-PhP.B was
administered IV or IStr. Significantly higher vector genome
levels were retrieved from the striatum (Figure 5C) and the
cortex (Figure 5D) of mice administered with AAV5-miRNA IStr
compared with the other experimental groups. When compared
to an IV administration of AAV9-PhP.B, a 22-fold and 15-fold
higher vector distribution was achieved in the striatum and
cortex, respectively. The levels of miRNA following AAV had a
similar pattern as vector DNA found in the striatum (Figure 5E)
and the cortex (Figure 5F).
DISCUSSION
In this study, AAV9-PhP.B and AAV5-PhP.B were produced in
the baculovirus expression system and showed to transduce cells
in vitro. Subsequently, these constructs were evaluated in vivo.
Although the addition of PhP.B does not enhance BBB crossing
of serotype GFP-carrying AAV5, it does increase GFP mRNA
expression in the liver. We found that the addition of PhP.B to
AAV9 enhances the capability of the vector to cross the BBB,
as found in the earlier studies (Deverman et al., 2016; Morabito
et al., 2017; Hordeaux et al., 2018), and, when applied at a
sufficient dose, GFP expression can be noted throughout the
brain from the medulla to the cortex. IStr and IV administration
of AAV9-PhP.B mediated similar transduction levels in the cortex
and striatum. When we compared IStr administration of AAV5 to
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FIGURE 4 | GFP expression throughout the brain of mice administered with AAV9-PhP.B. (A) Cartoon depicting construct used, administration route, and dose used
of 4 × 1012 GC/mouse. Brains were extracted, fixed in 4% paraformaldehyde, embedded in gelatin, and serially cut by using a Vibratome to 50-µm sections. GFP
protein staining (shown in brown) in (B) the medulla, (C) the locus coeruleus, (D) the thalamus, (E) the hippocampus, (F) the striatum, and (G) the cortex. Rectangles
show the location of the micrograph taken. The black scale bar represents 50 µm, and white bar represents 250 µm.
IV administration of AAV9, AAV5 IStr was superior in terms of
transducing the cortex and striatum.
Overall, we observed lower transduction levels with AAV9
vectors using a similar dose as described in the study first
describing PhP.B (Deverman et al., 2016). The difference in
the quantification method per laboratory could be a possible
explanation for observed differences. In addition, for AAV9,
varying results are reported between laboratories with regard
to the distribution patterns. For example, in one of the first
studies, predominant astrocyte transduction (Foust et al., 2008)
was reported while another laboratory observed the transduction
of neurons (Gray et al., 2011). Another observation is more
variation in the group of animals administered IStr compared
with the IV-injected group. Vector spread after the striatal
infusion is not homogenous throughout the tissue since this is
performed with concentrated vector directly into tissue resulting
in local differences. Therefore, more variation is observed
between mice. We suspected that transfer of a homogenous
dilution in blood from the endothelium to the striatal area occurs
in a more homogenous manner and is, therefore, less sensitive to
variation between animals.
The addition of PhP.B to AAV5 resulted in increased
transgene mRNA in the liver compared with AAV5. Ly6a is
constitutively expressed by liver sinusoidal endothelial cells
(LSEC) (Luna et al., 2004). The LSEC form a permeable barrier
between the bloodstream and hepatocytes (Poisson et al., 2017).
In the brain, the interaction between AAV9-PhP.B and Ly6A
facilitates the crossing of the BBB. Since we did not note
the crossing of the BBB by AAV5-PhP.B, the LSEC may be
transduced rather than the hepatocytes underneath.
A recent publication (Powell et al., 2020) showed that
AAV9 after infection could mediate expression in different
cell types in the brain, depending on the promoter used.
Moreover, a six alanine insertion after the VP2 start residue
results in a shift from oligodendrocyte to neuronal transduction.
The addition of PhP.B to AAV could also have an effect
on the specific cells transduced within the tissue. Recently,
RNAscope in situ hybridization revealed the precise location
of the vector DNA and mRNA produced, while identifying
specific cells by IHC (Zhao et al., 2020). This method could
be applied in the future to investigate and differentiate
between level of vector entry and transgene expression in
a specific cell. In our case, this would be a method to
investigate the liver transduction by AAV5-PhP.B. Since this
method is beyond the scope of this study, we did not
pursue this further.
The question remains why AAV9 is enhanced by PhP.B to
cross the BBB, while AAV5 is not. The mechanism by which
AAV crosses the BBB has not been fully understood. AAV9
appears to cross the BBB by transcytosis in an in vitro human
BBB model by a yet unknown receptor (Merkel et al., 2017).
The data in mice indicated that AAV9-PhP.B crosses the BBB by
transcytosis of brain microvascular endothelial cells (Matsuzaki
et al., 2019). The results of this study with AAV5-PhP.B indicate
that PhP.B alone is not enough for an AAV particle to cross
the endothelial barrier. Therefore, it appears PhP.B facilitates
the transduction of endothelial cells which in turn enables the
enhanced trafficking of AAV9 through the endothelium from
apical to basolateral side by another co-receptor. For AAV5-
PhP.B endocytosis and trandusction of the endothelium might
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FIGURE 5 | Vector distribution and miRNA expression in mice brain after IV or intrastriatal (IStr) delivery. (A) A graphical representation of vectors used in this study.
The expression cassette used consisted of CAG-promoter-miRNA and poly(A) tail. (B) Administration routes at which mice were either administered intravenously (IV)
or IStr. (C) Distribution in the striatum. A significantly higher amount of vector DNA was observed in the striatum and cortex of mice that received AAV5 IStr. For
AAV5, direct administration results in significantly higher distribution, while for AAV9-PhP.B, similar amounts of the vector were retrieved on average. (D) Distribution
in the cortex. In the cortex, the same pattern is observed as in the striatum. The IStr administration of AAV5 results in higher amounts of vector DNA than the IV
administration of AAV9-PhP.B or AAV5 IV. (E) miRNA levels in the striatum and (F) miRNA levels in cortex. The vector DNA results translate to miRNA expression
levels. In this study, we also observed higher miRNA levels in mice administered AAV5 IStr compared with AAV9-PhP.B IV and AAV5-PhP.B. ND stands for not
detected. Statistical analysis was performed by the one-way ANOVA, followed by the Bonferroni multiple comparisons test. Asterisks indicate a statistical
significance of ∗p ≤ 0.05, ∗∗p < 0.005, ∗∗∗p ≤ 0.001, and ∗∗∗∗p < 0.0001.
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still occur but the astrocytes and neurons underneath remain
untransduced.
The addition of different peptides to the corresponding
position I587 in AAV2 enhanced the AAV2 ability to transduce
the CNS after IV administration (Chen et al., 2009). Therefore, it
is theoretically possible to add a peptide to an AAV serotype other
than AAV9 and increase BBB crossing. Each of the serotypes
uses a different primary receptor. AAV2 binds to heparin sulfate
proteoglycan (HSPG), AAV9 to N-linked galactose receptors, and
AAV5 to N-linked sialic acid (Vance et al., 2015). However, both
AAV2 and AAV9 use laminin receptor (LamR) as a secondary
receptor, while AAV5 also binds the platelet-derived growth
factor receptor (PDGF-R) (Vance et al., 2015). The interplay
between these various receptors appears to play a role in various
transduction patterns.
The AAV9-based IV therapy in combination with a PhP.B
designed for primate could be a viable option for diseases with
multifocal pathologies where different types of cells in the body
are affected, such as lysosomal storage diseases (Tardieu et al.,
2017). In most cases, ideally, therapy should be applied as early as
possible before irreversible neurodegeneration occurs (Massaro
et al., 2020). Due to the more permissiveness of the BBB, newborn
babies need a lower dose for disease correction, implying a lower
risk of the therapy. In diseases where the whole body is genetically
affected, the systemic mechanism of AAV9-primate PhP.B might
even be an advantage.
For a clinical application, a primate permissive version of
PhP.B should be developed. A putative human equivalent of
murine Ly6a, the receptor to which PhP.B binds, is Ly6E. The
Ly6E protein is highly expressed in human BBB endothelial
cells. Furthermore, a peptide sequence within HIV-GP120 is
hypothesized as a potential binding motif functioning as a
primate permissive PhP.B (Ille et al., 2020). This peptide
could be used to develop a human variant of AAV9-PhP.B
to be tested in nonhuman primates or in vitro systems that
mimic the human BBB.
Our results further show that the direct administration of
AAV5 represents an attractive strategy for diseases where the
deeper brain areas have to be targeted. AAV5 has been studied
for localized administration to various CNS targets such as
intrathalamic pathway (Samaranch et al., 2017) in the deep
cerebellar nuclei (Martier et al., 2019b) and IStr. The IStr
administration of AAV5 has been extensively studied in multiple
models. Our current transduction results are in line with those
of a rodent preclinical HD model in which disease amelioration
was achieved (Spronck et al., 2019). The IStr administration of
AAV5 has also been studied in nonhuman primates (Samaranch
et al., 2017) and minipigs (Evers et al., 2018). A similar
transduction pattern is observed across all studied species, with
high transduction and transgene expression levels in the striatum
and cortex. A clinical study using the IStr administration of AAV5
has been initiated in patients with HD (NCT04120493).
We studied the transduction and miRNA expression in the
cortex and striatum following AAV delivery. Irrespective of the
delivery method, similar transduction and transgene expression
levels are observed in the brain with AAV9-PhP.B, showing that
for an AAV9 vector with PhP.B or similar enhancement, there
would be no added benefit of an IStr over IV delivery. From the
standpoint of a clinical program targeting solely the striatum and
the connection areas, it is worth investing in IStr delivery with
AAV5 rather than further optimizing AAV9 or another capsid to
reach the striatum after IV delivery.
Taken together, our results show that for therapies where high
levels of transduction are needed, the direct delivery of AAV5 is
a viable option. For treatments in which a wide viral spreading
throughout the brain and body is desired, a human-targeting
variant of AAV9-PhP.B is an attractive candidate.
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